Tecan Group Past Earnings Performance
Past criteria checks 3/6
Tecan Group has been growing earnings at an average annual rate of 8.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 12.8% per year. Tecan Group's return on equity is 7.2%, and it has net margins of 10.1%.
Key information
8.2%
Earnings growth rate
6.4%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 12.8% |
| Return on equity | 7.2% |
| Net Margin | 10.1% |
| Next Earnings Update | 12 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tecan Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,000 | 101 | 192 | 64 |
| 31 Mar 24 | 1,037 | 117 | 192 | 67 |
| 31 Dec 23 | 1,074 | 132 | 192 | 70 |
| 30 Sep 23 | 1,088 | 120 | 198 | 74 |
| 30 Jun 23 | 1,102 | 109 | 205 | 78 |
| 31 Mar 23 | 1,123 | 115 | 209 | 78 |
| 31 Dec 22 | 1,144 | 121 | 214 | 78 |
| 30 Sep 22 | 1,110 | 113 | 212 | 79 |
| 30 Jun 22 | 1,077 | 105 | 210 | 79 |
| 31 Mar 22 | 1,012 | 113 | 201 | 76 |
| 31 Dec 21 | 947 | 122 | 192 | 72 |
| 30 Sep 21 | 911 | 136 | 192 | 70 |
| 30 Jun 21 | 875 | 150 | 191 | 68 |
| 31 Mar 21 | 803 | 127 | 182 | 65 |
| 31 Dec 20 | 731 | 104 | 172 | 62 |
| 30 Sep 20 | 691 | 94 | 160 | 59 |
| 30 Jun 20 | 651 | 84 | 149 | 56 |
| 31 Mar 20 | 644 | 79 | 149 | 58 |
| 31 Dec 19 | 637 | 73 | 149 | 60 |
| 30 Sep 19 | 627 | 70 | 150 | 59 |
| 30 Jun 19 | 616 | 67 | 151 | 59 |
| 31 Mar 19 | 605 | 69 | 146 | 55 |
| 31 Dec 18 | 594 | 71 | 141 | 51 |
| 30 Sep 18 | 582 | 70 | 139 | 50 |
| 30 Jun 18 | 570 | 69 | 138 | 49 |
| 31 Mar 18 | 559 | 67 | 137 | 50 |
| 31 Dec 17 | 549 | 66 | 136 | 50 |
| 30 Sep 17 | 536 | 62 | 132 | 49 |
| 30 Jun 17 | 523 | 57 | 129 | 48 |
| 31 Mar 17 | 515 | 56 | 127 | 47 |
| 31 Dec 16 | 506 | 55 | 125 | 47 |
| 30 Sep 16 | 491 | 55 | 123 | 45 |
| 30 Jun 16 | 476 | 55 | 120 | 43 |
| 31 Mar 16 | 458 | 56 | 115 | 41 |
| 31 Dec 15 | 440 | 57 | 110 | 40 |
| 30 Sep 15 | 434 | 52 | 108 | 41 |
| 30 Jun 15 | 427 | 48 | 106 | 42 |
| 31 Mar 15 | 413 | 44 | 104 | 41 |
| 31 Dec 14 | 400 | 40 | 103 | 39 |
| 30 Sep 14 | 389 | 44 | 99 | 40 |
| 30 Jun 14 | 378 | 48 | 95 | 41 |
| 31 Mar 14 | 383 | 47 | 93 | 43 |
| 31 Dec 13 | 388 | 46 | 92 | 45 |
Quality Earnings: 0QLN has high quality earnings.
Growing Profit Margin: 0QLN's current net profit margins (10.1%) are higher than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0QLN's earnings have grown by 8.2% per year over the past 5 years.
Accelerating Growth: 0QLN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0QLN had negative earnings growth (-6.7%) over the past year, making it difficult to compare to the Life Sciences industry average (5.4%).
Return on Equity
High ROE: 0QLN's Return on Equity (7.2%) is considered low.